Alan Gordon Fraser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alan Gordon Fraser has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Lynnette R. Ferguson
Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand
6 shared publications - Angharad R. Morgan
Discipline of Nutrition, FMHS, The University of Auckland, Auckland, New Zealand
3 shared publications - Dug Yeo Han
Discipline of Nutrition and Dietetics, FM&HS, The University of Auckland, Auckland, New Zealand
3 shared publications D. P. Jewell
Gastroenterology Unit, University of Oxford, Radcliffe Infirmary, Oxford, UK
2 shared publicationsMark Lane
MercyAscot, Auckland, New Zealand
2 shared publications- Nishi Karunasinghe
Auckland Cancer Society Research Centre (ACSRC), Faculty of Medical and Health Sciences (FM&HS), The University of Auckland, Auckland, New Zealand
2 shared publications
Latest Publications
- Open Access
- 29 April 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 9 (1) , 19
The Development of the Women’s Wellness Program for Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a chronic, relapsing, remitting functional disorder of the gut, characterised by abdominal pain, bloating, and changes in bowel habits, and associated with poor quality of life and depression. A common disorder in primary and specialty care, IBS affects 10–18% of New Zealanders and imposes significant personal, societal, and economic burdens. Although it is a condition of both mind and body, there is no holistic support program for people with IBS in Aotearoa. This project aimed: (1) To explore the impact of IBS with affected women and their health professionals. (2) Determine whether the Australian Women’s Wellness Program is adaptable, acceptable, and feasible for women in Aotearoa with IBS. (3) To codesign a prototype Women’s Wellness (IBS Aotearoa) program with affected women and their clinicians ready for feasibility testing. Eligible IBS participants (n = 15) comprising women 18 years or over, and legally able to consent, and separately health professionals or researchers (n = 15) working in the field of IBS participated in an in-depth individual or focus group interview. They were asked questions about their IBS journey, including diagnosis and treatment. Their feedback detailed how IBS adversely affected all aspects of quality of life, raised issues with diagnosis and treatment and articulated desired support approaches. When given information about the Women’s Wellness program and asked to provide feedback on it, all 30 interviewed participants agreed that a Women’s Wellness program health promotion approach for IBS was feasible, relevant, and warranted. A lifestyle program prototype based on the Women’s Wellness Program, tailored for those with IBS and led by an trained IBS health professional, is developed from these data ready for feasibility testing.
- 29 April 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 9 (1) , 19
Open AccessThe Development of the Women’s Wellness Program for Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a chronic, relapsing, remitting functional disorder of the gut, characterised by abdominal pain, bloating, and changes in bowel habits, and associated with poor quality of life and depression. A common disorder in primary and specialty care, IBS affects 10–18% of New Zealanders and imposes significant personal, societal, and economic burdens. Although it is a condition of both mind and body, there is no holistic support program for people with IBS in Aotearoa. This project aimed: (1) To explore the impact of IBS with affected women and their health professionals. (2) Determine whether the Australian Women’s Wellness Program is adaptable, acceptable, and feasible for women in Aotearoa with IBS. (3) To codesign a prototype Women’s Wellness (IBS Aotearoa) program with affected women and their clinicians ready for feasibility testing. Eligible IBS participants (n = 15) comprising women 18 years or over, and legally able to consent, and separately health professionals or researchers (n = 15) working in the field of IBS participated in an in-depth individual or focus group interview. They were asked questions about their IBS journey, including diagnosis and treatment. Their feedback detailed how IBS adversely affected all aspects of quality of life, raised issues with diagnosis and treatment and articulated desired support approaches. When given information about the Women’s Wellness program and asked to provide feedback on it, all 30 interviewed participants agreed that a Women’s Wellness program health promotion approach for IBS was feasible, relevant, and warranted. A lifestyle program prototype based on the Women’s Wellness Program, tailored for those with IBS and led by an trained IBS health professional, is developed from these data ready for feasibility testing.
- Open Access
- 29 December 2021
- Published by Scientific Archives
- Vol. 2 (4)
Colonoscopy Audit Increases Detection of Sessile Serrated Polyps
- 29 December 2021
- Published by Scientific Archives
- Vol. 2 (4)
Open AccessColonoscopy Audit Increases Detection of Sessile Serrated Polyps
- 8 October 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (9) , 1527-1528
Methotrexate or azathioprine—do differing rates of discontinuation settle the debate?
- 8 October 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (9) , 1527-1528
Methotrexate or azathioprine—do differing rates of discontinuation settle the debate?
- Open Access
- 16 July 2020
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 7 (1) , e000425
Improved detection of adenomas and sessile serrated polyps is maintained with continuous audit of colonoscopy
Background The audit process may help improve performance indicators for colonoscopy quality but it is unclear whether this is sustained over several years. Methods 44138 procedures for 28 endoscopists from 2004 to 2019 were analysed for polyp detection rate and withdrawal time. From 2012, 14 endoscopists were analysed with additional data on polyp histology and number of polyps removed. Results Polyp detection increased from 40.7% in 2004 to 62.2% in 2019; removal of polyps>1 cm remained constant (11%). Adenoma detection rate was 25.8% in 2012 and 28.3% in 2019. Sessile serrated polyp (SSP) detection rate increased from 4.5% to 14.7%; most of the increase was in the first 2 years of the histology part of the audit. There was a significant correlation of adenoma detection rate with mean number of adenomas (r=0.72, p=0.004) and a significant correlation of SSP detection with mean number of SSPs (r=0.85, p=0.0001). Conclusion The audit process appears to encourage a higher rate of polyp detection. This was due to increased detection of smaller polyps and increased detection of SSPs.
- 16 July 2020
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 7 (1) , e000425
Open AccessImproved detection of adenomas and sessile serrated polyps is maintained with continuous audit of colonoscopy
Background The audit process may help improve performance indicators for colonoscopy quality but it is unclear whether this is sustained over several years. Methods 44138 procedures for 28 endoscopists from 2004 to 2019 were analysed for polyp detection rate and withdrawal time. From 2012, 14 endoscopists were analysed with additional data on polyp histology and number of polyps removed. Results Polyp detection increased from 40.7% in 2004 to 62.2% in 2019; removal of polyps>1 cm remained constant (11%). Adenoma detection rate was 25.8% in 2012 and 28.3% in 2019. Sessile serrated polyp (SSP) detection rate increased from 4.5% to 14.7%; most of the increase was in the first 2 years of the histology part of the audit. There was a significant correlation of adenoma detection rate with mean number of adenomas (r=0.72, p=0.004) and a significant correlation of SSP detection with mean number of SSPs (r=0.85, p=0.0001). Conclusion The audit process appears to encourage a higher rate of polyp detection. This was due to increased detection of smaller polyps and increased detection of SSPs.
- 1 November 2018
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 114, 58-61
Predicting patient reassurance after colonoscopy: The role of illness beliefs
- 1 November 2018
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 114, 58-61
Predicting patient reassurance after colonoscopy: The role of illness beliefs
- 4 August 2017
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 46 (5) , 550-551
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori
Linked ContentThis article is linked to Jung and Bardhan papers. To view these articles visit https://doi.org/10.1111/apt.14206 and https://doi.org/10.1111/apt.14130.
- 4 August 2017
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 46 (5) , 550-551
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori
Linked ContentThis article is linked to Jung and Bardhan papers. To view these articles visit https://doi.org/10.1111/apt.14206 and https://doi.org/10.1111/apt.14130.
- 24 February 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (5) , 570-577
Medical specialists' attitudes to prescribing biosimilars
Purpose: Biosimilars are a cost‐effective alternative to biologics that could improve patients' access to expensive biological medicines. Currently, there are little data on doctors' perceptions of biosimilars and in what situations they are comfortable prescribing biosimilars. In this study, we investigated medical specialists' perceptions of biosimilars and the factors associated with the acceptance of biosimilars.Methods: A national sample of 110 of 327 medical specialists working in the areas of rheumatology, dermatology, gastroenterology, oncology and haematology completed an online questionnaire examining attitudes towards prescribing biosimilars, indication extrapolation and switching patients to a biosimilar.Results: Most specialists held positive views of biosimilars, with between 54 and 74% confident in the safety, efficacy, manufacturing and pharmacovigilance of biosimilars. Seventy‐one percent of specialists agreed that they would prescribe biosimilars for all or some conditions meeting relevant clinical criteria. Specialists were less confident about indication extrapolation and switching patients from an existing biologic. Acceptance of biosimilars was significantly associated with a lower perceived time to explain a biosimilar to a patient and lower number of weekly patient appointments. The most common situations that they would not prescribe a biosimilar was where there was a lack of clinical data supporting efficacy (32%), or evidence of adverse effects (17%).Conclusions: Medical specialists held generally positive attitudes towards biosimilars but were less confident in indication extrapolation and switching patients from a biologic. Providing clinicians with guidance on how to explain biosimilars to patients and written patient material may help overcome some of the barriers to the use of biosimilars. Copyright © 2017 John Wiley & Sons, Ltd.
- 24 February 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (5) , 570-577
Medical specialists' attitudes to prescribing biosimilars
Purpose: Biosimilars are a cost‐effective alternative to biologics that could improve patients' access to expensive biological medicines. Currently, there are little data on doctors' perceptions of biosimilars and in what situations they are comfortable prescribing biosimilars. In this study, we investigated medical specialists' perceptions of biosimilars and the factors associated with the acceptance of biosimilars.Methods: A national sample of 110 of 327 medical specialists working in the areas of rheumatology, dermatology, gastroenterology, oncology and haematology completed an online questionnaire examining attitudes towards prescribing biosimilars, indication extrapolation and switching patients to a biosimilar.Results: Most specialists held positive views of biosimilars, with between 54 and 74% confident in the safety, efficacy, manufacturing and pharmacovigilance of biosimilars. Seventy‐one percent of specialists agreed that they would prescribe biosimilars for all or some conditions meeting relevant clinical criteria. Specialists were less confident about indication extrapolation and switching patients from an existing biologic. Acceptance of biosimilars was significantly associated with a lower perceived time to explain a biosimilar to a patient and lower number of weekly patient appointments. The most common situations that they would not prescribe a biosimilar was where there was a lack of clinical data supporting efficacy (32%), or evidence of adverse effects (17%).Conclusions: Medical specialists held generally positive attitudes towards biosimilars but were less confident in indication extrapolation and switching patients from a biologic. Providing clinicians with guidance on how to explain biosimilars to patients and written patient material may help overcome some of the barriers to the use of biosimilars. Copyright © 2017 John Wiley & Sons, Ltd.
- 17 February 2017
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 45 (6) , 857-858
Editorial: can we get more clinical benefit from thiopurine metabolite testing?
Linked ContentThis article is linked to Wong and Coenen et al and Hooymans papers. To view these articles visit https://doi.org/10.1111/apt.13879 and https://doi.org/10.1111/apt.13955.
- 17 February 2017
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 45 (6) , 857-858
Editorial: can we get more clinical benefit from thiopurine metabolite testing?
Linked ContentThis article is linked to Wong and Coenen et al and Hooymans papers. To view these articles visit https://doi.org/10.1111/apt.13879 and https://doi.org/10.1111/apt.13955.
- 4 July 2016
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 44 (3) , 300-301
Editorial: serologic microbial‐associated markers to predict Crohn's disease behaviour
- 4 July 2016
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 44 (3) , 300-301
Editorial: serologic microbial‐associated markers to predict Crohn's disease behaviour
- 4 May 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 41 (11) , 1210
Editorial:post hocanalysis of SONIC trial
- 4 May 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 41 (11) , 1210
Editorial:post hocanalysis of SONIC trial